Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

BACKGROUND: Monoclonal antibodies acting on the calcitonin gene-related peptide (CGRP) or its receptor have changed migraine preventive treatment. Those treatments have led to reconsidering the outcomes of migraine prevention. Available data mostly considered benefits in terms of relative efficacy (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ornello, Raffaele, Baraldi, Carlo, Guerzoni, Simona, Lambru, Giorgio, Andreou, Anna P., Raffaelli, Bianca, Gendolla, Astrid, Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Cevoli, Sabina, Favoni, Valentina, Vernieri, Fabrizio, Altamura, Claudia, Russo, Antonio, Silvestro, Marcello, Valle, Elisabetta Dalla, Mancioli, Andrea, Ranieri, Angelo, Alfieri, Gennaro, Latysheva, Nina, Filatova, Elena, Talbot, Jamie, Cheng, Shuli, Holle, Dagny, Scheffler, Armin, Nežádal, Tomáš, Čtrnáctá, Dana, Šípková, Jitka, Matoušová, Zuzana, Casalena, Alfonsina, Maddestra, Maurizio, Viola, Stefano, Affaitati, Giannapia, Giamberardino, Maria Adele, Pistoia, Francesca, Reuter, Uwe, Sacco, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933935/
https://www.ncbi.nlm.nih.gov/pubmed/35305579
http://dx.doi.org/10.1186/s10194-022-01408-w

Ejemplares similares

Ejemplares similares